Francesco De Rosa
Overview
Explore the profile of Francesco De Rosa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
57
Citations
672
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sorrentino F, Di Terlizzi P, De Rosa F, Salati C, Spadea L, Gagliano C, et al.
World J Transplant
. 2024 Dec;
14(4):97690.
PMID: 39697450
New frontiers about retinal cell transplantation for retinal degenerative diseases start from the idea that acting on stem cells can help regenerate retinal layers and establish new synapses among retinal...
2.
Ridolfi L, Gurrieri L, Riva N, Bulgarelli J, De Rosa F, Guidoboni M, et al.
Front Immunol
. 2024 Aug;
15:1404861.
PMID: 39192978
Background: Glioblastoma (GBM) is a poor prognosis grade 4 glioma. After surgical resection, the standard therapy consists of concurrent radiotherapy (RT) and temozolomide (TMZ) followed by TMZ alone. Our previous...
3.
Granato A, Pancisi E, Piccinini C, Stefanelli M, Pignatta S, Soldati V, et al.
Cytotherapy
. 2024 Jul;
26(12):1547-1555.
PMID: 39046388
Background Aims: Dendritic cells (DCs) are professional antigen-presenting cells of the mammalian immune system. Ex vivo differentiated DCs represent a unique Advanced Therapy Medicinal Product (ATMP), used in several clinical...
4.
Sorrentino F, De Rosa F, Di Terlizzi P, Toneatto G, Gabai A, Finocchio L, et al.
World J Clin Oncol
. 2024 Jan;
15(1):23-31.
PMID: 38292657
Uveal melanoma (UM) is the most common primary intraocular cancer in adults. The incidence in Europe and the United States is 6-7 per million population per year. Although most primary...
5.
Miserocchi G, Bassi M, De Luca G, Calpona S, De Rosa F, Bongiovanni A, et al.
Front Oncol
. 2023 Oct;
13:1245043.
PMID: 37795450
Background: Polymorphous adenocarcinoma (PAC) represents the second most widespread neoplasm of the minor salivary glands. These tumors rarely develop a histological progression from low-grade to high-grade malignancy, named "high-grade transformation"...
6.
Valpione S, Campana L, Weightman J, Salih Z, Galvani E, Mundra P, et al.
Eur J Cancer
. 2022 Nov;
177:164-174.
PMID: 36347135
Background: Immune cell-driven anti-cancer activity is paramount for effective responses to checkpoint inhibitors (ICB). However, the contribution of the different immune cell subsets in the circulation and within the tumour...
7.
Marconcini R, Fava P, Nuzzo A, Manacorda S, Ferrari M, De Rosa F, et al.
Front Oncol
. 2022 Sep;
12:917999.
PMID: 36046043
Background: BRAF and MEK inhibitors target therapies (TT) and AntiPD1 immunotherapies (IT) are available first-line treatments for BRAF v600 mutant metastatic melanoma patients. ECOG PS (E), baseline LDH (L), and...
8.
Pancisi E, Granato A, Scarpi E, Ridolfi L, Carloni S, Moretti C, et al.
Vaccines (Basel)
. 2022 Jul;
10(7).
PMID: 35891165
Advanced therapy medical products (ATMPs) are rapidly growing as innovative medicines for the treatment of several diseases. Hence, the role of quality analytical tests to ensure consistent product safety and...
9.
Busca A, Gabrielli G, Sidoti F, Costa C, Giaccone L, Dogliotti I, et al.
Bone Marrow Transplant
. 2022 Jul;
57(10):1604-1606.
PMID: 35842475
No abstract available.
10.
Miserocchi G, Spadazzi C, Calpona S, De Rosa F, Usai A, De Vita A, et al.
J Pers Med
. 2022 Jun;
12(6).
PMID: 35743639
Head and neck cancers (HNCs) represent the sixth most widespread malignancy worldwide. Surgery, radiotherapy, chemotherapeutic and immunotherapeutic drugs represent the main clinical approaches for HNC patients. Moreover, HNCs are characterised...